Table 1. Subject demographics.
| Study 1 | Control | Parkinson’s Disease |
|---|---|---|
| Number | 13 | 15 |
| Age (years) | 67 ± 1.4 | 68 ± 1.5 |
| Gender | 4M/10F | 11M/4F |
| Disease Duration (months) | — | 37 ± 8 |
| Levodopa equivalent dose (mg) | — | 707 ± 35 |
| MDS UPDRS (total score) | — | 20 ± 3 |
| Study 2 | Control | Parkinson’s Disease |
| Number | 12 | 12 |
| Age (years) | 68 ± 2.6 | 64 ± 2.7 |
| Gender | 8M/4F | 10M/2F |
| Disease Duration (months) | — | 65 ± 13 |
| Levodopa equivalent dose (mg) | — | 735 ± 58 |
| MDS UPDRS (total score) | — | 22 ± 2.5 |
Demographic data for subjects involved in this study. MDS-UPDRS = Movement Disorder Society Unified Parkinson’s Disease Rating Scale. Data are mean ± SEM.